TandemAI
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What TandemAI does
TandemAI is a privately held drug discovery technology company founded in 2021 that operates an integrated AI- and physics-based computational platform combined with wet lab experimentation capabilities. Its core product is TandemViz, a cloud-based browser workspace that unifies proprietary computational modules — including TandemFEP (free energy perturbation with quantum-mechanics-derived force fields), TandemGen (generative AI for molecular ideation), TandemADMET (ML-based ADMET prediction), TandemDynamics, TandemDock, TandemAnalytics, TandemSandbox, and a QuickCycle integrated dry-wet workflow — with tools for tracking synthesis (TandemQueue) and managing experimental data. The platform supports hit identification, hit-to-lead and lead optimization, scaffold hopping, ADMET prediction, and virtual screening, and has been used to deliver a development candidate in under 18 months for partners including Perpetual Medicines and Third Rock Ventures.
The company monetizes through two primary models: FTE-based service contracts that bundle wet lab services (medicinal chemistry, synthetic chemistry, biological assays, structural biology) with complimentary access to TandemViz computational tools, and standalone SaaS software licensing of the TandemViz platform with optional GPU services and virtual private cloud deployment. Its go-to-market is direct enterprise sales targeting biopharmaceutical and biotech firms in the US and China, supplemented by academic and biotech partnerships, industry symposia (Boston, Cambridge), webinars, and content marketing.
TandemAI is headquartered in New York with operations in Cambridge (Massachusetts), Suzhou, and Shanghai, employing over 350 professionals including 50+ AI and computational chemistry scientists and 200+ synthetic chemists. The company has raised over $80M across a $25M seed/pre-Series A (December 2021, OrbiMed and Chengwei Capital), $35M Series A (October 2023, Qiming Venture Partners), and $22M Series A extension (November 2025, V-Capital and KHK Fund). In July 2025, TandemAI merged with Perpetual Medicines to extend the platform into peptide therapeutics, and in May 2026 partnered with Mila to apply world models to drug discovery simulation. The company serves over 150 biopharmaceutical clients globally, with reported quantitative outcomes including at least 50% reduction in hit-to-lead and lead optimization timelines and a 5x expansion of design space.
TandemAI firmographics
Firmographics- Name
- TandemAI
- Legal name
- TandemAI US, LLC / TandemAI Suzhou Co., Ltd.
- Website
- https://tandemai.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
TandemAI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Scientific Research and Development Services (5417), Software Publishers (5132), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro industry
- Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Keywords
Where TandemAI is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
TandemAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- FTE-Based Service Contracts: Full-Time Equivalent (FTE) pricing model where clients pay for wet lab services and receive complimentary access to TandemAI's proprietary computational and AI tools. Includes medicinal chemistry, synthetic chemistry, biological assays, and computational drug discovery services. Flexible engagement modes include traditional FTE, flexible FTE, and fee-for-service (FFS).
- SaaS Software Licensing: Stand-alone software license (SaaS) model providing access to TandemViz platform and all its computational modules including TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, and TandemSandbox. Optional GPU services and virtual private cloud (VPC) deployment available.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Hybrid | Multi-year contract | FTE-Based Wet Lab + Computational Tools |
| Subscription | Annual | SaaS Standalone Software License |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
TandemAI product offering
Product offeringCore offering
TandemAI provides an integrated drug discovery platform combining physics-based computational methods (FEP, molecular dynamics) and generative AI molecular design with large-scale wet lab experimentation. The core software product is TandemViz, a cloud-based browser workspace integrating computational modules (TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, TandemSandbox) with wet lab workflow management. The offering is delivered either as FTE-based CRO services bundling wet lab work with complimentary computational tool access, or as standalone SaaS licensing of the TandemViz platform with optional GPU services and VPC deployment.
Product overview
TandemAI is an integrated drug discovery technology company offering a cloud-based platform called TandemViz that combines AI-driven and physics-based computational methods with wet lab experimentation capabilities. The platform architecture consists of TandemViz as the core unified workspace integrating multiple computational modules (TandemFEP for binding affinity calculations, TandemGen for generative AI molecular design, TandemADMET for ADMET prediction, TandemDynamics for molecular simulations, TandemDock for molecular docking, TandemAnalytics for structure-activity analysis, TandemSandbox for structural modeling, TandemFilters for molecule filtering, TandemQueue for synthesis tracking, TandemVault for data management, TandemScreen for virtual screening) with wet lab services including medicinal chemistry, biological assays, and a dedicated peptide platform. Available via FTE service pricing or SaaS software license with optional GPU services and VPC deployment.
Differentiator
Problem solved
Functional benefit
Brands
- TandemViz: Next-generation cloud-enabled discovery platform that integrates access to physics-based and AI in-silico drug design software with tools to manage and analyze wet lab results.
- TandemFEP
- TandemGen
- TandemADMET
- TandemDock
- TandemDynamics
- TandemAnalytics
- TandemSandbox
- QuickCycle
- CoreHop-FEP / CBFE
Products and services
- TandemViz Cloud-based drug discovery platform integrating physics-based and AI computational tools with wet lab data management, enabling collaboration across computational and experimental workflows for biopharma and biotech customers.
- Medicinal Chemistry & Synthesis Service Synthetic and medicinal chemistry services including synthesis from milligrams to kilograms, with capabilities in PROTACs, molecular glues, and conjugated drugs, performed by a 200+ chemist team.
- Biological Assays Service Comprehensive biological services including protein production, biochemical assays, cell-based assays, biophysical assays, and structural biology via X-ray crystallography for biopharma discovery programs.
- Hit Identification Service Comprehensive hit finding using virtual screening, pharmacophore screening, fragment screening, and DEL screening approaches, powered by the TandemScreen virtual screening platform.
- Hit-to-Lead and Lead Optimization Service Computational tools and wet lab services for multi-parameter optimization of potency, selectivity, and pharmacokinetic properties during hit-to-lead and lead optimization phases.
- Peptide Platform AI computational design platform for peptide therapeutics with automated synthesis capabilities, covering oncology, metabolic, and autoimmune disease targets.
- Digital Assays & Workflows In silico assays including binding affinity predictions, ADMET predictions, virtual HTS, and QuickCycle workflow for reducing drug discovery timelines, available as part of the integrated service offering.
Quantifiable outcome
- Hit-to-lead and lead optimization timelines reduced by at least 50%
- +5 more outcomes
Companies that use TandemAI
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
TandemAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature16 records
TandemAI partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship.
- Third Rock VenturesflagshipThird Rock Ventures partnered with Perpetual Medicines (now part of TandemAI following the 2025 merger) to deliver a development candidate in under 18 months using TandemAI's computational physics and AI-driven platform. The partnership paired Perpetual Medicines' specialized drug hunting and design capabilities with Third Rock Ventures' strategic and therapeutic expertise. The successful outcome establishes a blueprint for venture capital and cutting-edge computational platform collaboration.
- Mila (Quebec Artificial Intelligence Institute)flagshipMila, the Quebec Artificial Intelligence Institute, partnered with TandemAI to apply world models—machine learning frameworks traditionally used in video games and autonomous vehicles—to accelerate drug discovery. The collaboration leverages Mila's deep learning expertise and TandemAI's TandemViz platform to simulate complex chemical interactions with greater accuracy. Both organizations are committed to open science and responsible AI development, emphasizing knowledge sharing and accessibility within the scientific community.
- Perpetual MedicinesflagshipPerpetual Medicines and TandemAI announced a strategic merger in July 2025 to expand physics and AI-based drug discovery capabilities. Perpetual Medicines leverages TandemAI's integrated platform, and the merger created an expanded integrated AI-enabled small molecule and peptide discovery platform. Perpetual Medicines used the combined platform to deliver a development candidate for Third Rock Ventures in under 18 months.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
TandemAI competitors and assessment
Company assessmentDirect peers
- Schrödinger: Public computational drug discovery company combining physics-based methods (FEP+, Glide) with a SaaS platform and collaborative drug discovery services. Most directly comparable to TandemAI's physics-and-AI plus integrated platform model, with overlapping customers in biopharma R&D.
- Atomwise: AI-driven small molecule discovery company using structure-based deep learning for hit identification and optimization. Comparable to TandemAI's virtual screening, generative design, and pharma/biotech partnership model.
- XtalPi: China-headquartered AI and quantum physics-based drug discovery company offering integrated computational chemistry plus wet lab services. Closest geographic and product-model peer to TandemAI, with similar FTE plus SaaS GTM to global biopharma.
- Insilico Medicine: AI-driven drug discovery company with end-to-end platform spanning target identification, generative chemistry, and internal pipeline assets. Comparable to TandemAI's full-stack AI/physics approach and its evolution toward asset creation through partnerships and internal programs.
- Recursion Pharmaceuticals: Public AI drug discovery company combining high-throughput wet lab biology with machine learning for target and molecule discovery. Comparable to TandemAI on the thesis that integrated dry/wet lab plus AI is the winning model for preclinical R&D.
- Insitro: Machine learning-driven drug discovery company partnering with pharma (e.g., Lilly, BMS) on target ID and chemistry. Comparable to TandemAI's enterprise pharma partnership model, though Insitro is more biology/genomics-led while TandemAI emphasizes chemistry and physics.
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction (AlphaFold) and generative chemistry to pharma collaborations. A well-capitalized direct competitor in AI-driven molecular design with major pharma partnerships.
Emerging players
- Iambic Therapeutics: AI-driven drug discovery company combining physics-based and machine-learning models for small molecule design, with an internal pipeline. Comparable emerging-stage peer focused on generative chemistry and physics-informed modeling.
- Cradle Bio: AI protein design and engineering company serving biotech and pharma R&D teams via a SaaS-style platform. Adjacent emerging peer using generative AI to expand design space, conceptually similar to TandemGen and virtual screening capabilities.
Broad incumbents
- Charles River Laboratories: Large public CRO providing integrated drug discovery and preclinical services, including computational chemistry and medicinal chemistry. Broad incumbent offering overlapping wet-lab discovery services, but as part of a much wider portfolio rather than a specialized AI/physics platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
TandemAI social profiles
Digital presenceTandemAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
TandemAI leadership team
Management profileNumber of profiles
Profiles6 records
TandemAI funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TandemAI M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TandemAI
What does TandemAI do?
TandemAI provides an integrated drug discovery platform combining physics-based computational methods (FEP, molecular dynamics) and generative AI molecular design with large-scale wet lab experimentation. The core software product is TandemViz, a cloud-based browser workspace integrating computational modules (TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, TandemSandbox) with wet lab workflow management. The offering is delivered either as FTE-based CRO services bundling wet lab work with complimentary computational tool access, or as standalone SaaS licensing of the TandemViz platform with optional GPU services and VPC deployment.
Is TandemAI a public or private company?
TandemAI is a private company. It is classified as venture growth investor backed and is currently operating.
When was TandemAI founded?
TandemAI was founded in 2021. It employs 51 to 100 people.
Where is TandemAI based?
TandemAI is headquartered in New York, United States, in the North America region.
How does TandemAI make money?
Two revenue lines are on record. FTE-Based Service Contracts are the primary driver. The others are saaS Software Licensing.
Who are TandemAI's main competitors?
Direct peers on record are Schrödinger, Atomwise, XtalPi, Insilico Medicine, Recursion Pharmaceuticals, Insitro and Isomorphic Labs. Emerging players are Iambic Therapeutics and Cradle Bio. Charles River Laboratories is listed as a broad incumbent.
Does TandemAI have an API?
No public API is recorded for TandemAI.
What industry is TandemAI in?
TandemAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand). Its NAICS code is 5417 and its SIC code is 8731.